Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Drugs in Pipeline
149
Phase 3 Programs
107
Upcoming Catalysts
15
Next Catalyst
Jan 27, 2026
6dStock performance and market intelligence
15 upcoming, 0 past
Primary completion for Fenebrutinib trial (NCT04586010) in Relapsing Multiple Sclerosis
SourcePrimary completion for Teriflunomide trial (NCT04586010) in Relapsing Multiple Sclerosis
SourcePrimary completion for Giredestrant trial (NCT05634499) in Endometrial Cancer
SourcePrimary completion for Entrectinib trial (NCT02650401) in Solid Tumors
SourcePrimary completion for Placebo trial (NCT06863961) in Atopic Dermatitis
SourcePrimary completion for Afimkibart trial (NCT06863961) in Atopic Dermatitis
SourcePrimary completion for Phesgo trial (NCT05894239) in Metastatic Breast Cancer
SourcePrimary completion for Placebo trial (NCT05894239) in Metastatic Breast Cancer
SourcePrimary completion for Satralizumab trial (NCT06450639) in Duchenne Muscular Dystrophy
SourcePrimary completion for Alectinib trial (NCT03178552) in Non-Small Cell Lung Cancer
SourcePrimary completion for Atezolizumab trial (NCT03178552) in Non-Small Cell Lung Cancer
SourcePrimary completion for Pemetrexed trial (NCT03178552) in Non-Small Cell Lung Cancer
SourcePrimary completion for Tobemstomig trial (NCT05852691) in Breast Cancer
SourcePrimary completion for Pertuzumab trial (NCT02320435) in Solid Tumors
SourcePrimary completion for Ranibizumab trial (NCT04657289) in Neovascular Age-related Macular Degeneration (nAMD)
SourceMachine learning insights and smart money movement
Pending NDA/BLA submissions with predicted PDUFA dates
Clinical development programs and drug candidates
Epoetin Beta
Anemia
Ibandronate
Pain; Bone Neoplasms; Neoplasm Metastasis
RO7239361
Duchenne Muscular Dystrophy
obinutuzumab
Lymphocytic Leukemia, Chronic
r-HuEPO
Anemia
Interferon alfa 2a [Roferon]
Renal Cell Cancer
Interferon beta-1a
Relapsing Multiple Sclerosis
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Renal Cell Carcinoma
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Triple-negative Breast Cancer
Tiragolumab
Esophageal Cancer
Aflibercept
Macular Edema
Nab-paclitaxel
Breast Cancer
Folic acid or folate
Rheumatoid Arthritis
5-Fluorouracil (5-FU)
Colorectal Cancer
Evidence-based medical care for Acute Coronary Syndrome
Coronary Heart Disease
Antihistamine
Multiple Sclerosis
Pemetrexed
Non-Small Cell Lung Cancer
Vincristine
Non-Hodgkin's Lymphoma
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Anemia
Disease-modifying anti-rheumatic drugs
Rheumatoid Arthritis
Becavizumab
Hepatocellular Carcinoma
Inavolisib
Breast Cancer
Crizotinib
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
capecitabine [Xeloda]
Gastric Cancer
rFVIIa
Hemophilia A
Taxotere
Breast Cancer
Ribavirin
Hepatitis C
Cobimetinib
Solid Tumors
Baloxavir Marboxil
Influenza
Phesgo
Metastatic Breast Cancer
peginterferon alfa-2a [Pegasys]
Hepatitis C, Chronic
Carboplatin
Cervical Cancer
vemurafenib
Malignant Melanoma
Fluoropyrimidine-based Chemotherapy
Colorectal Cancer
Pertuzumab
Solid Tumors
Trastuzumab [Herceptin]
Gastric Cancer
CDK4/6i
Breast Cancer
Pembrolizumab
Non-small Cell Lung Cancer (NSCLC)
Fenebrutinib
Relapsing Multiple Sclerosis
Ranibizumab
Neovascular Age-related Macular Degeneration (nAMD)
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Diabetic Retinopathy
cisplatin
Non-Squamous Non-Small Cell Lung Cancer
Faricimab
Choroidal Neovascularization
Satralizumab
Duchenne Muscular Dystrophy
Erlotinib
Non-Small Cell Lung Cancer
Trastuzumab emtansine
Breast Cancer
Cyclophosphamide
Leukemia, Lymphocytic, Chronic, B-Cell
Peginterferon alfa-2a
Hepatitis C, Chronic
Mycophenolate mofetil
Myelodysplastic Syndromes
Fingolimod
Relapsing-Remitting Multiple Sclerosis
Darbepoetin alfa
Anemia
Glofitamab
Large B-Cell Lymphoma
mycophenolate mofetil [CellCept]
Myasthenia Gravis Generalised
Nelfinavir mesylate
HIV Infections
Teriflunomide
Relapsing Multiple Sclerosis
bitopertin [RO4917838]
Schizophrenia
ibandronate [Bonviva/Boniva]
Osteoporosis
Taxane-based chemotherapy
Breast Cancer
methotrexate
Rheumatoid Arthritis
Entrectinib
Carcinoma, Non-Small-Cell Lung
Ocrelizumab
Multiple Sclerosis
rituximab
Rheumatoid Arthritis
Atezolizumab
Breast Cancer
Bevacizumab
Malignant Melanoma
Tocilizumab
Rheumatoid Arthritis
mycophenolate mofetil (CellCept)
Myasthenia Gravis, Generalized
DMARDs
Rheumatoid Arthritis
Cyclosporine
Renal Transplantation
23-PPV
Multiple Sclerosis, Relapsing-Remitting
bevacizumab [Avastin]
Non-Small Cell Lung Cancer
Methylprednisolone
Rheumatoid Arthritis
MabThera/Rituxan
Rheumatoid Arthritis
mycophenolate mofetil (MMF)
Heart Transplantation
rituximab [MabThera/Rituxan]
Non-Hodgkin's Lymphoma
RO7234292
Huntingtons Disease
Gemcitabine
Triple Negative Breast Neoplasms
Trastuzumab
Gastric Cancer
epoetin beta [NeoRecormon]
Anemia
FAP IL2V
Cancer
Entecavir
Pediatric Immuno-Tolerant Chronic Hepatitis B
Alimta or Taxotere
Non-Small Cell Lung Cancer
Etoposide
Carcinoma, Small Cell Lung
Oxaliplatin 130 mg/m^2
Colorectal Cancer
Doxorubicin
Breast Cancer
Paclitaxel
Breast Cancer
Chlorambucil
Lymphocytic Leukemia, Chronic
tocilizumab [RoActemra/Actemra]
Juvenile Idiopathic Arthritis
Mosunetuzumab
Non-Hodgkin Lymphoma
Emicizumab
Von Willebrand Disease, Type 3
Capecitabine
Metastatic Breast Cancer
Afimkibart
Rheumatoid Arthritis
Lebrikizumab
Atopic Dermatitis
methoxy polyethylene glycol-epoetin beta [Mircera]
Anemia
Vamikibart
Uveitic Macular Edema
Alectinib
Non-Small Cell Lung Cancer
docetaxel
Non-Squamous Non-Small Cell Lung Cancer
aleglitazar
Diabetes Mellitus Type 2
Methoxy polyethylene glycol-epoetin beta
Renal Anemia, Chronic
Dalcetrapib (RO4607381)
Coronary Heart Disease
FEC Chemotherapy
Breast Cancer
Non-steroidal anti-inflammatory drugs (NSAIDs)
Juvenile Idiopathic Arthritis
Ipatasertib
Cancer
Crovalimab
Paroxysmal Nocturnal Hemoglobinuria
Saquinavir
HIV Infections
Oseltamivir IV
Influenza
Oseltamivir
Influenza
Sorafenib
Carcinoma, Hepatocellular
Mosunetuzumab (IV)
Follicular Lymphoma
Risdiplam
Muscular Atrophy, Spinal
eloxatin
Colorectal Cancer
enfuvirtide [Fuzeon]
HIV Infections
Tobemstomig
Breast Cancer
Vismodegib
Basal Cell Carcinoma
RO4998452
Diabetes Mellitus Type 2
Standard chemotherapy
Breast Cancer
Zidovudine
HIV Infections
Actos
Diabetes Mellitus Type 2
Tiragolumab and Atezolizumab IV FDC
PD-L1-selected Solid Tumors
Polatuzumab Vedotin
Non-Hodgkin's Lymphoma
Enfuvirtide
HIV Infections
DPP-IV Inhibitor
Diabetes Mellitus Type 2
Giredestrant
Endometrial Cancer
Acetaminophen/paracetamol
Lupus Nephritis
RG7314
Autism Spectrum Disorder
Tociliuzumab
COVID-19 Pneumonia
PEGASYS [peginterferon alfa-2a]
Hepatitis B, Chronic
Oxaliplatin
Gastric and Gastroesophageal Junction Carcinoma
Irinotecan
Colorectal Cancer
Ribociclib
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
MSTT1041A
Asthma
Metformin
Diabetes Mellitus Type 2
Herceptin
Breast Neoplasms
RO4917838
Schizophrenia
RO7017773
Autism Spectrum Disorder (ASD)
RO 205-2349
Diabetes
Inhaled corticposteroids (ICS)
Asthma
LABA
Asthma
erlotinib [Tarceva]
Non-Squamous Non-Small Cell Lung Cancer
GK Activator (2)
Diabetes Mellitus Type 2
Danoprevir
Hepatitis C, Chronic
Zifibancimig
Macular Degeneration
RO5024048
Hepatitis C, Chronic
fludarabine
Lymphocytic Leukemia, Chronic
RO4602522
Alzheimer's Disease
Copegus
Hepatitis C, Chronic
Atezolizumab (MPDL3280A) [TECENTRIQ]
Lymphoma, Follicular
Prasinezumab
Parkinsons Disease
FOLFIRI
Colorectal Cancer
RO7247669
Melanoma
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Epoetin Beta | Phase 3 | Anemia | - |
Ibandronate | Phase 3 | Pain; Bone Neoplasms; Neoplasm Metastasis | - |
RO7239361 | Phase 3 | Duchenne Muscular Dystrophy | - |
obinutuzumab | Phase 3 | Lymphocytic Leukemia, Chronic | - |
r-HuEPO | Phase 3 | Anemia | - |
Interferon alfa 2a [Roferon] | Phase 3 | Renal Cell Cancer | - |
Interferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - |
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Phase 3 | Renal Cell Carcinoma | - |
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody | Phase 3 | Triple-negative Breast Cancer | - |
Tiragolumab | Phase 3 | Esophageal Cancer | - |
Aflibercept | Phase 3 | Macular Edema | - |
Nab-paclitaxel | Phase 3 | Breast Cancer | - |
Folic acid or folate | Phase 3 | Rheumatoid Arthritis | - |
5-Fluorouracil (5-FU) | Phase 3 | Colorectal Cancer | - |
Evidence-based medical care for Acute Coronary Syndrome | Phase 3 | Coronary Heart Disease | - |
Antihistamine | Phase 3 | Multiple Sclerosis | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - |
Vincristine | Phase 3 | Non-Hodgkin's Lymphoma | - |
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Phase 3 | Anemia | - |
Disease-modifying anti-rheumatic drugs | Phase 3 | Rheumatoid Arthritis | - |
Becavizumab | Phase 3 | Hepatocellular Carcinoma | - |
Inavolisib | Phase 3 | Breast Cancer | - |
Crizotinib | Phase 3 | Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer | - |
capecitabine [Xeloda] | Phase 3 | Gastric Cancer | - |
rFVIIa | Phase 3 | Hemophilia A | - |
Taxotere | Phase 3 | Breast Cancer | - |
Ribavirin | Phase 3 | Hepatitis C | - |
Cobimetinib | Phase 3 | Solid Tumors | - |
Baloxavir Marboxil | Phase 3 | Influenza | - |
Phesgo | Phase 3 | Metastatic Breast Cancer | - |
peginterferon alfa-2a [Pegasys] | Phase 3 | Hepatitis C, Chronic | - |
Carboplatin | Phase 3 | Cervical Cancer | - |
vemurafenib | Phase 3 | Malignant Melanoma | - |
Fluoropyrimidine-based Chemotherapy | Phase 3 | Colorectal Cancer | - |
Pertuzumab | Phase 3 | Solid Tumors | - |
Trastuzumab [Herceptin] | Phase 3 | Gastric Cancer | - |
CDK4/6i | Phase 3 | Breast Cancer | - |
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - |
Fenebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - |
Ranibizumab | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD) | - |
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab | Phase 3 | Diabetic Retinopathy | - |
cisplatin | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
Faricimab | Phase 3 | Choroidal Neovascularization | - |
Satralizumab | Phase 3 | Duchenne Muscular Dystrophy | - |
Erlotinib | Phase 3 | Non-Small Cell Lung Cancer | - |
Trastuzumab emtansine | Phase 3 | Breast Cancer | - |
Cyclophosphamide | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - |
Peginterferon alfa-2a | Phase 3 | Hepatitis C, Chronic | - |
Mycophenolate mofetil | Phase 3 | Myelodysplastic Syndromes | - |
Fingolimod | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - |
Darbepoetin alfa | Phase 3 | Anemia | - |
Glofitamab | Phase 3 | Large B-Cell Lymphoma | - |
mycophenolate mofetil [CellCept] | Phase 3 | Myasthenia Gravis Generalised | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis | - |
bitopertin [RO4917838] | Phase 3 | Schizophrenia | - |
ibandronate [Bonviva/Boniva] | Phase 3 | Osteoporosis | - |
Taxane-based chemotherapy | Phase 3 | Breast Cancer | - |
methotrexate | Phase 3 | Rheumatoid Arthritis | - |
Entrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - |
Ocrelizumab | Phase 3 | Multiple Sclerosis | - |
rituximab | Phase 3 | Rheumatoid Arthritis | - |
Atezolizumab | Phase 3 | Breast Cancer | - |
Bevacizumab | Phase 3 | Malignant Melanoma | - |
Tocilizumab | Phase 3 | Rheumatoid Arthritis | - |
mycophenolate mofetil (CellCept) | Phase 3 | Myasthenia Gravis, Generalized | - |
DMARDs | Phase 3 | Rheumatoid Arthritis | - |
Cyclosporine | Phase 3 | Renal Transplantation | - |
23-PPV | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - |
bevacizumab [Avastin] | Phase 3 | Non-Small Cell Lung Cancer | - |
Methylprednisolone | Phase 3 | Rheumatoid Arthritis | - |
MabThera/Rituxan | Phase 3 | Rheumatoid Arthritis | - |
mycophenolate mofetil (MMF) | Phase 3 | Heart Transplantation | - |
rituximab [MabThera/Rituxan] | Phase 3 | Non-Hodgkin's Lymphoma | - |
RO7234292 | Phase 3 | Huntingtons Disease | - |
Gemcitabine | Phase 3 | Triple Negative Breast Neoplasms | - |
Trastuzumab | Phase 3 | Gastric Cancer | - |
epoetin beta [NeoRecormon] | Phase 3 | Anemia | - |
FAP IL2V | Phase 3 | Cancer | - |
Entecavir | Phase 3 | Pediatric Immuno-Tolerant Chronic Hepatitis B | - |
Alimta or Taxotere | Phase 3 | Non-Small Cell Lung Cancer | - |
Etoposide | Phase 3 | Carcinoma, Small Cell Lung | - |
Oxaliplatin 130 mg/m^2 | Phase 3 | Colorectal Cancer | - |
Doxorubicin | Phase 3 | Breast Cancer | - |
Paclitaxel | Phase 3 | Breast Cancer | - |
Chlorambucil | Phase 3 | Lymphocytic Leukemia, Chronic | - |
tocilizumab [RoActemra/Actemra] | Phase 3 | Juvenile Idiopathic Arthritis | - |
Mosunetuzumab | Phase 3 | Non-Hodgkin Lymphoma | - |
Emicizumab | Phase 3 | Von Willebrand Disease, Type 3 | - |
Capecitabine | Phase 3 | Metastatic Breast Cancer | - |
Afimkibart | Phase 3 | Rheumatoid Arthritis | - |
Lebrikizumab | Phase 3 | Atopic Dermatitis | - |
methoxy polyethylene glycol-epoetin beta [Mircera] | Phase 3 | Anemia | - |
Vamikibart | Phase 3 | Uveitic Macular Edema | - |
Alectinib | Phase 3 | Non-Small Cell Lung Cancer | - |
docetaxel | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - |
aleglitazar | Phase 3 | Diabetes Mellitus Type 2 | - |
Methoxy polyethylene glycol-epoetin beta | Phase 3 | Renal Anemia, Chronic | - |
Dalcetrapib (RO4607381) | Phase 3 | Coronary Heart Disease | - |
FEC Chemotherapy | Phase 3 | Breast Cancer | - |
Non-steroidal anti-inflammatory drugs (NSAIDs) | Phase 3 | Juvenile Idiopathic Arthritis | - |
Ipatasertib | Phase 3 | Cancer | - |
Crovalimab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - |
Saquinavir | Phase 3 | HIV Infections | - |
Oseltamivir IV | Phase 3 | Influenza | - |
Oseltamivir | Phase 3 | Influenza | - |
Sorafenib | Phase 3 | Carcinoma, Hepatocellular | - |
Mosunetuzumab (IV) | Phase 2 | Follicular Lymphoma | - |
Risdiplam | Phase 2 | Muscular Atrophy, Spinal | - |
eloxatin | Phase 2 | Colorectal Cancer | - |
enfuvirtide [Fuzeon] | Phase 2 | HIV Infections | - |
Tobemstomig | Phase 2 | Breast Cancer | - |
Vismodegib | Phase 2 | Basal Cell Carcinoma | - |
RO4998452 | Phase 2 | Diabetes Mellitus Type 2 | - |
Standard chemotherapy | Phase 2 | Breast Cancer | - |
Zidovudine | Phase 2 | HIV Infections | - |
Actos | Phase 2 | Diabetes Mellitus Type 2 | - |
Tiragolumab and Atezolizumab IV FDC | Phase 2 | PD-L1-selected Solid Tumors | - |
Polatuzumab Vedotin | Phase 2 | Non-Hodgkin's Lymphoma | - |
Enfuvirtide | Phase 2 | HIV Infections | - |
DPP-IV Inhibitor | Phase 2 | Diabetes Mellitus Type 2 | - |
Giredestrant | Phase 2 | Endometrial Cancer | - |
Acetaminophen/paracetamol | Phase 2 | Lupus Nephritis | - |
RG7314 | Phase 2 | Autism Spectrum Disorder | - |
Tociliuzumab | Phase 2 | COVID-19 Pneumonia | - |
PEGASYS [peginterferon alfa-2a] | Phase 2 | Hepatitis B, Chronic | - |
Oxaliplatin | Phase 2 | Gastric and Gastroesophageal Junction Carcinoma | - |
Irinotecan | Phase 2 | Colorectal Cancer | - |
Ribociclib | Phase 2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | - |
MSTT1041A | Phase 2 | Asthma | - |
Metformin | Phase 2 | Diabetes Mellitus Type 2 | - |
Herceptin | Phase 2 | Breast Neoplasms | - |
RO4917838 | Phase 2 | Schizophrenia | - |
RO7017773 | Phase 2 | Autism Spectrum Disorder (ASD) | - |
RO 205-2349 | Phase 2 | Diabetes | - |
Inhaled corticposteroids (ICS) | Phase 2 | Asthma | - |
LABA | Phase 2 | Asthma | - |
erlotinib [Tarceva] | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - |
GK Activator (2) | Phase 2 | Diabetes Mellitus Type 2 | - |
Danoprevir | Phase 2 | Hepatitis C, Chronic | - |
Zifibancimig | Phase 2 | Macular Degeneration | - |
RO5024048 | Phase 2 | Hepatitis C, Chronic | - |
fludarabine | Phase 2 | Lymphocytic Leukemia, Chronic | - |
RO4602522 | Phase 2 | Alzheimer's Disease | - |
Copegus | Phase 2 | Hepatitis C, Chronic | - |
Atezolizumab (MPDL3280A) [TECENTRIQ] | Phase 2 | Lymphoma, Follicular | - |
Prasinezumab | Phase 2 | Parkinsons Disease | - |
FOLFIRI | Phase 2 | Colorectal Cancer | - |
RO7247669 | Phase 2 | Melanoma | - |
Approvals, filings, and latest developments